GlassScriptPhysician profile
Pinkus Goldberg
NPI 1740262641
$89,092.31
in general payments reported to CMS, 2019-2025
22 companies · $953 in 2025
The $953 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81K · 2020: $4,211 · 2021: $431 · 2022: $324 · 2023: $2,076 · 2024: $418 · 2025: $953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,347 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,347.39 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $38,248.99 | 2019-2023 | |
| Shire North American Group INC | $19,099.14 | 2019 | |
| Genentech USA, INC. | $15,003.08 | 2019-2023 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $7,782.41 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $4,243.00 | 2020-2023 | Takhzyro |
| Astrazeneca Pharmaceuticals LP | $976.35 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Novartis Pharmaceuticals Corporation | $696.17 | 2019-2025 | |
| Blueprint Medicines Corporation | $602.35 | 2022-2024 | Ayvakit |
| Genzyme Corporation | $465.94 | 2023-2025 | |
| Genentech, INC. | $327.06 | 2023-2025 | Xolair |
| Covis Pharma Gmbh | $300.14 | 2021-2022 | |
| Circassia INC. | $271.06 | 2019 | |
| Glaxosmithkline, LLC. | $237.18 | 2023-2025 | Nucala, Trelegy Ellipta |
| Octapharma USA, INC. | $173.75 | 2019-2023 | Cutaquig |
| Regeneron Healthcare Solutions, INC. | $144.84 | 2021-2023 | Dupixent |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $123.26 | 2019 | |
| Optinose US, INC. | $111.23 | 2019-2021 | |
| Ars Pharmaceuticals Operations, INC. | $92.87 | 2025 | Neffy |
| Csl Behring | $88.94 | 2019-2023 | Haegarda, Hizentra |
| Incyte Corporation | $58.25 | 2025 | Opzelura |
| Amgen INC. | $30.21 | 2023 | Tezspire |
| Biocryst US Sales Co., LLC | $16.09 | 2023 | Orladeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pinkus Goldberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.